Research & News


Our News 

MD Biosciences Expands Histology and IHC Capabilities

New laboratories serving growing activity on clinical assay development and analysis front


Weizmann Science Park, Israel, (27 February 2017) - MD Biosciences announces the expansion of its histology and IHC preclinical and clinical services. The expansion encompasses new laboratories at the Nes Ziona facility with an expanded footprint, automation, plus additional new team members.

This expansion accomodates MD Biosciences' growing activity in the development of assays for novel biomarkers in preclinical, translational and clinical applications. MD Biosciences is uniquely positioned to identify and develop biomarker assays as early as preclinical phases and follow these through clinical studies. The laboratory is led by Dr. Avital Schauder and supported by a highly experienced team of scientists.

 Screen Shot 2017-02-03 at 1.14.38 PM.png

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.